Rivaroxaban for Treatment in Venous or Arterial Thrombosis in Neonates
Status:
Completed
Trial end date:
2017-12-18
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out whether rivaroxaban is safe and effective to use in
children age newborn to less than 6 months and how long it stays in the body and how it is
used in the body. Safety will be assessed by looking at the incidence and types of bleeding
events. There will also be a check for worsening of blood clots.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Bayer
Collaborators:
Janssen Pharmaceuticals Inc Janssen Research & Development, LLC